Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PEG-Ara-C conjugates for controlled release.

O Schiavon1, G Pasut, S Moro

  • 1Department of Pharmaceutical Sciences, University of Padua, via F. Marzolo 5, 35131 Padua, Italy.

European Journal of Medicinal Chemistry
|February 28, 2004
PubMed
Summary

Poly(ethylene glycol) (PEG) was conjugated to the antitumour agent 1-beta-D arabinofuranosilcytosyne (Ara-C) to enhance its stability and circulation time. The resulting PEG-Ara-C conjugates showed improved in vivo performance and reduced cytotoxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Species differences in opsonization and phagocyte recognition of preclinical poly-2-alkyl-2-oxazoline-coated nanoparticles.

Nature communications·2025
Same author

Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates.

Journal of controlled release : official journal of the Controlled Release Society·2024
Same author

Center of mass-based posturography for free living environment applications.

Clinical biomechanics (Bristol, Avon)·2023
Same author

The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines.

Nature nanotechnology·2021
Same author

Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.

Journal of controlled release : official journal of the Controlled Release Society·2021
Same author

Muscular activation changes in lower limbs after underwater gait training in Parkinson's disease: A surface emg pilot study.

Gait & posture·2020

Area of Science:

  • Bioconjugation Chemistry
  • Drug Delivery Systems
  • Polymer Science

Background:

  • The antitumour agent 1-beta-D arabinofuranosilcytosyne (Ara-C) exhibits limited in vivo stability and short blood residence time.
  • Developing effective drug delivery systems is crucial for improving the therapeutic efficacy of cytotoxic agents like Ara-C.

Purpose of the Study:

  • To synthesize and characterize poly(ethylene glycol) (PEG) conjugates of Ara-C to enhance its pharmacokinetic properties and reduce toxicity.
  • To investigate the impact of PEG molecular weight, architecture, and drug loading on the stability and efficacy of Ara-C conjugates.

Main Methods:

  • Synthesis of eight PEG-Ara-C conjugates using linear or branched PEG (5-20 kDa) via an amino acid spacer.
  • Functionalization of PEG hydroxyl groups with bicarboxylic amino acids to create tetrafunctional derivatives for increased drug loading.

Related Experiment Videos

  • Computer graphic analysis to assess steric hindrance and optimize conjugate structure.
  • Evaluation of synthesis and purification methods for low free drug content.
  • In vitro studies on hydrolysis and deamination of PEG-Ara-C.
  • In vivo pharmacokinetic studies in mice and in vitro cytotoxicity assays against HeLa cells.

    • Main Results:

    • Optimized synthesis and purification yielded PEG-Ara-C products with minimal free Ara-C.
    • PEG-Ara-C conjugates demonstrated increased stability against hydrolysis and deamination compared to free Ara-C.
    • Pharmacokinetic studies in mice showed significantly prolonged blood residence time for the conjugates.
    • Cytotoxicity assays revealed reduced toxicity of PEG-Ara-C conjugates towards HeLa cells compared to the free drug, especially for highly loaded conjugates.

    Conclusions:

    • Covalent linkage of Ara-C to PEG effectively improves its in vivo stability and pharmacokinetic profile.
    • PEGylation of Ara-C offers a promising strategy for developing more effective and less toxic cancer therapies.
    • The developed PEG-Ara-C conjugates represent a significant advancement in targeted drug delivery for antitumour applications.